重性抑郁初始治疗实现持续应答的系统综述与网络Meta分析
该网络Meta分析纳入81项RCT共13722例成人重性抑郁患者,比较心理治疗、抗抑郁药、联合治疗与常规治疗的持续应答。结果显示联合治疗和心理治疗在维持期持续应答上优于抗抑郁药单药和常规治疗,提示初始治疗选择或需更新。
要点
- 联合治疗持续应答优于抗抑郁药单药(OR=2.52,95%CI 1.66-3.85,持续至维持期)。
- 心理治疗持续应答优于抗抑郁药单药(OR=1.53,95%CI 1.00-2.35,持续至维持期)。
- 以常规治疗平均持续应答率29%计,心理治疗或联合治疗的风险差异为12至16个百分点。
核心结论
- 心理治疗和联合治疗比抗抑郁药单药具有更持久的疗效,初始治疗选择指南可能需要相应更新。
研究设计与样本
- 系统综述与网络Meta分析,纳入81项RCT共13722例成人重性抑郁患者。
- 急性期随机接受心理治疗、规范化抗抑郁药、联合治疗、常规治疗或安慰剂,并随访至维持期。
- 持续应答定义为急性期应答且维持期无抑郁复发,维持期平均42.2±16.2周(范围24-104周),提取近12个月时间点数据。
主要发现
- 联合治疗持续应答优于抗抑郁药单药:持续至维持期OR=2.52(95%CI 1.66-3.85),后续 discretionary 治疗OR=1.80(95%CI 1.21-2.67)。
- 联合治疗持续应答优于常规治疗:持续至维持期OR=2.90(95%CI 1.68-5.01),后续 discretionary 治疗OR=1.97(95%CI 1.51-2.58)。
- 心理治疗持续应答优于抗抑郁药单药:持续至维持期OR=1.53(95%CI 1.00-2.35),后续 discretionary 治疗OR=1.66(95%CI 1.13-2.44)。
- 心理治疗与常规治疗比较:持续至维持期OR=1.76(95%CI 0.97-3.21),后续 discretionary 治疗OR=1.83(95%CI 1.20-2.78)。
- 以常规治疗平均持续应答率29%为基线,心理治疗或联合治疗相较于抗抑郁药或常规治疗的风险差异为12至16个百分点。
关键数值与推荐
- 持续应答定义为对急性期治疗应答且维持期无抑郁复发,数据提取近12个月时间点。
- 联合治疗 vs 抗抑郁药单药持续至维持期OR=2.52(95%CI 1.66-3.85)。
- 心理治疗 vs 抗抑郁药单药持续至维持期OR=1.53(95%CI 1.00-2.35)。
- 常规治疗平均持续应答率为29%,心理治疗或联合治疗的优势转化为12至16个百分点的风险差异。
临床怎么用
- 初始治疗选择心理治疗或联合治疗可能比抗抑郁药单药更有利于维持长期应答。
- 临床决策时可结合患者偏好与可及性,优先考虑心理治疗或联合治疗以降低复发风险。
局限性
- 急性期治疗可延续至维持期、换药或 discretionary 治疗,治疗策略异质性可能影响结果解释。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
Major depression is often a relapsing disorder. It is therefore important to start its treatment with therapies that maximize the chance of not only getting the patients well but also keeping them well. We examined the associations between initial treatments and sustained response by conducting a network meta-analysis of randomized controlled trials (RCTs) in which adult patients with major depression were randomized to acute treatment with a psychotherapy (PSY), a protocolized antidepressant pharmacotherapy (PHA), their combination (COM), standard treatment in primary or secondary care (STD), or pill placebo, and were then followed up through a maintenance phase. By design, acute phase treatment could be continued into the maintenance phase, switched to another treatment or followed by discretionary treatment. We included 81 RCTs, with 13,722 participants. Sustained response was defined as responding to the acute treatment and subsequently having no depressive relapse through the maintenance phase (mean duration: 42.2±16.2 weeks, range 24-104 weeks). We extracted the data reported at the time point closest to 12 months. COM resulted in more sustained response than PHA, both when these treatments were continued into the maintenance phase (OR=2.52, 95% CI: 1.66-3.85) and when they were followed by discretionary treatment (OR=1.80, 95% CI: 1.21-2.67). The same applied to COM in comparison with STD (OR=2.90, 95% CI: 1.68-5.01 when COM was continued into the maintenance phase; OR=1.97, 95% CI: 1.51-2.58 when COM was followed by discretionary treatment). PSY also kept the patients well more often than PHA, both when these treatments were continued into the maintenance phase (OR=1.53, 95% CI: 1.00-2.35) and when they were followed by discretionary treatment (OR=1.66, 95% CI: 1.13-2.44). The same applied to PSY compared with STD (OR=1.76, 95% CI: 0.97-3.21 when PSY was continued into the maintenance phase; OR=1.83, 95% CI: 1.20-2.78 when PSY was followed by discretionary treatment). Given the average sustained response rate of 29% on STD, the advantages of PSY or COM over PHA or STD translated into risk differences ranging from 12 to 16 percentage points. We conclude that PSY and COM have more enduring effects than PHA. Clinical guidelines on the initial treatment choice for depression may need to be updated accordingly.
引用
- Furukawa TA, Shinohara K, Sahker E, et al. Initial treatment choices to achieve sustained response in major depression: a systematic review and network meta-analysis. World Psychiatry. 2021. PMID: 34505365. doi:10.1002/wps.20906
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。